Neuroendocrine tumors: Recent progress in diagnosis and treatment

Endocrine-Related Cancer

Volumn 18, Issue SUPPL. 1, 2011, Pages

  Oberg, Kjell ^a,b  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; BEVACIZUMAB; CAPECITABINE; CHORIONIC GONADOTROPIN; CHROMOGRANIN A; GASTRIN; GLUCAGON; INSULIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; NEURON SPECIFIC ENOLASE; PANCREAS POLYPEPTIDE; PENTETREOTIDE IN 111; PROTEIN TYROSINE KINASE; TEMOZOLOMIDE;

CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; EDITORIAL; HEALTH CARE COST; HEALTH CARE PERSONNEL; HUMAN; NEUROENDOCRINE TUMOR; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; SCINTIGRAPHY; URINE LEVEL;

DIAGNOSTIC IMAGING; HUMANS; NEUROENDOCRINE TUMORS; TUMOR MARKERS, BIOLOGICAL;

EID: 80054802269     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-10-0288     Document Type: Editorial

References (23)

1. 18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clinical Cancer Research 16 978-985. (doi:10.1158/1078-0432.CCR-09-1759)
2. Capella C, Solcia E, Sobin LH & Arnold R 2000 Endocrine tumours of the oesophagus. In Pathology and Genetics. Tumours of the Digestive System. WHO Classification of Tumours. Eds SR Hamilton & LA Aaltonen. Lyon: IARC Press.
3. Gabriel M, Hausler F, Bale R, Moncayo R, Decristoforo C, Kovacs P & Virgolini I 2005 Image fusion analysis of (99m)Tc-HYNIC-Tyr(3)-octreotide SPECT and diagnostic CT using an immobilisation device with external markers in patients with endocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging 32 1440-1451. (doi:10.1007/s00259-005-1875-z)
4. Janson ET, Holmberg L, Stridsberg M, Eriksson B, Theodorsson E, Wilander E & Oberg K 1997 Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Annals of Oncology 8 685-690. (doi:10.1023/A:1008215730767)
5. Khan MS & Caplin ME 2011 Therapeutic management of patients with gastroenteropancreatic neuroendocrine tumours. Endocrine-Related Cancer 18 (Supplement) S57-S78.
6. Klöppel G 2011 Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms. Endocrine-Related Cancer 18 (Supplement) S5-S20.
7. Kloppel G, Rindi G, Perren A, Komminoth P & Klimstra DS 2010 The ENETS AJCC/UICC TNM classifications of the neuroendocrine tumors of the gastrointestinal tract and the pancreas: a statement. Virchows Archiv 456 595-597. (doi:10.1007/s00428-010-0924-6)
8. 123I-Tyr3]- octreotide: the Rotterdam experience with more than 1000 patients. European Journal of Nuclear Medicine 20 716-731. (doi:10.1007/BF00181765)
9. Kulke MH 2006 A phase II study of temozolomide and bevacizumab in patients with advanced neuroendocrine tumors. ASCO Annual Meeting. Abstract No. 4044.
10. Kulke MH, Lenz HJ, Meropol NJ, Posey J, Ryan DP, Picus J, Bergsland E, Stuart K, Tye L, Huang X et al. 2008 Activity of sunitinib in patients with advanced neuroendocrine tumors. Journal of Clinical Oncology 26 3403-3410. (doi:10.1200/JCO.2007.15.9020)
11. Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, Feelders RA, van Aken MO &Krenning EP 2008 Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. Journal of Clinical Oncology 26 2124-2130. (doi:10.1200/JCO.2007.15. 2553)
12. Nobels FR, Kwekkeboom DJ, Coopmans W, Schoenmakers CH, Lindemans J, De Herder WW, Krenning EP, Bouillon R & Lamberts SW 1997 Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. Journal of Clinical Endocrinology and Metabolism 82 2622-2628. (doi:10.1210/jc.82.8.2622)
13. Oberg 2011 Circulating biomarkers in gastroenteropancreatic neuroendocrine tumours. Endocrine-Related Cancer 18 (Supplement) S21-S29.
14. Orlefors H, Sundin A, Garske U, Juhlin C, Oberg K, Skogseid B, Langstrom B, Bergstrom M & Eriksson B 2005 Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography. Journal of Clinical Endocrinology and Metabolism 90 3392-3400. (doi:10.1210/jc.2004-1938)
15. Ramage JK, Davies AH, Ardill J, Bax N, Caplin M, Grossman A, Hawkins R, McNicol AM, Reed N, Sutton R et al. 2005 Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut 54 (Supplement 4) iv1-iv16. (doi:10.1136/gut.2004.053314)
16. Ramage JK, Goretzki PE, Manfredi R, Komminoth P, Ferone D, Hyrdel R, Kaltsas G, Kelestimur F, Kvols L, Scoazec JY et al. 2008 Consensus guidelines for the management of patients with digestive neuroendocrine tumours: well-differentiated colon and rectum tumour/carcinoma. Neuroendocrinology 87 31-39. (doi:10.1159/000111036)
17. Rindi G, Kloppel G, Couvelard A, Komminoth P, Korner M, Lopes JM, McNicol AM, Nilsson O, Perren A, Scarpa A et al. 2007 TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Archiv 451 757-762. (doi:10.1007/s00428-007-0452-1)
18. Steinmuller T, Kianmanesh R, Falconi M, Scarpa A, Taal B, Kwekkeboom DJ, Lopes JM, Perren A, Nikou G, Yao J et al. 2008 Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 87 47-62. (doi:10.1159/000111037)
19. Teunissen JJM, Kwekkeboom DJ, Valkema R & Krenning EP 2011 Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours. Endocrine-Related Cancer 18 (Supplement) S31-S55.
20. Tomassetti P, Migliori M, Simoni P, Casadei R, De Iasio R, Corinaldesi R & Gullo L 2001 Diagnostic value of plasma chromogranin A in neuroendocrine tumours. European Journal of Gastroenterology & Hepatology 13 55-58. (doi:10.1097/00042737-200101000-00010)
21. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A et al. 2008a One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. Journal of Clinical Oncology 26 3063-3072. (doi:10.1200/JCO.2007.15.4377)
22. Yao JC, Phan AT, Chang DZ, Wolff RA, Hess K, Gupta S, Jacobs C, Mares JE, Landgraf AN, Rashid A et al. 2008b Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. Journal of Clinical Oncology 26 4311-4318. (doi:10.1200/JCO.2008.16.7858)
23. Yao JC, Lombard-Bohas C, Baudin E, Kvols LK, Rougier P, Ruszniewski P, Hoosen S, St Peter J, Haas T, Lebwohl D et al. 2010 Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. Journal of Clinical Oncology 28 69-76. (doi:10.1200/JCO.2009.24.2669)